Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy

Executive Summary

The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.

You may also be interested in...



Takeda's Investments In Data Science Seek Improved Trial Outcomes, R&D Efficiency

President of R&D Andrew Plump notes that much of the work to rationalize Takeda's pipeline after its Shire acquisition took place years ago when the Japanese pharma streamlined its R&D organization, but investments in data science to improve clinical trial outcomes and R&D efficiency are ongoing.

Takeda's Weber: ‘Everything Relies On Our Ability To Deliver Innovative Medicines’

With the formal completion of its huge acquisition of Shire now just a day away, some eight months after it was first announced, Takeda CEO presses home what he sees as the key priorities and benefits of the combined operation - but the real work to realize these is just beginning.

Takeda gains novel drug discovery tech through Envoy acquisition

Takeda's late 2010 research alliance with Envoy Therapeutics has led to the Japanese firm acquiring 100% of the privately held US CNS drug discovery specialist for up to $140 million in cash, in a deal expected to be finalized within the next few days.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125170

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel